Luoxis To Highlight RedoxSYS At Two Upcoming Scientific Conferences
ENGLEWOOD, Colo., Oct. 20, 2014 /PRNewswire/ -- Luoxis Diagnostics, Inc., a subsidiary of Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE), today announced that its academic collaborators will present several peer-reviewed posters highlighting the clinical and research potential for its novel RedoxSYS Diagnostic System, a first-in-class platform that measures oxidation-reduction potential (ORP) in the body in response to injury or illness. A poster demonstrating the clinical value of ORP as a clinical marker will be presented by Christopher V. Fanale, MD of Swedish Medical Center at the International Stroke Conference 2015, February 11-13, in Nashville, Tennessee. Three additional posters showcasing RedoxSYS' broad potential as a global, homeostatic measurement of oxidative stress will be presented at 21st annual meeting of The Society for Free Radical Biology and Medicine (SFBRM) November 19-23, 2014 in Seattle, Washington.
Josh Disbrow, Luoxis' President and Chief Executive Officer, stated, "Generating compelling clinical data, in collaboration with our academic partners, is a key element of our development strategy for our novel RedoxSYS diagnostic system. ORP's broad applicability in the areas of clinical practice and research continues to gain recognition, and we are proud to highlight the potential value of our first-in-class product in this peer-reviewed setting. In parallel, we continue to work with top-tier research collaborators to fully explore the multitude of acute care indications where measuring ORP may have a positive impact on patient outcomes."
International Stroke Conference Poster
- Poster Title: A Novel Method for Examining Oxidative Stress in Patients with Stroke Symptoms
Author(s): Christopher Fanale, MD; Jeffrey Wagner, MD; Kristin Salottolo, MPH; David Bar-Or, MD; Swedish Medical Center, Englewood, CO; Saint Anthony's Hospital, Lakewood, CO
Session Title: Experimental Mechanisms and Models Posters II
Session Date:Thursday, February 12, 2015; 6:15pm-6:45pm ET
Society for Free Radical Biology and Medicine Conference Posters
- Poster Title: A new method for assessing redox status: Application in strenuous exercise-induced oxidative stress
Author(s): Dimitrios Stagos; Nikolaos Goutzourelas; David Bar-Or, MD; Dimitrios Kouretas; University of Thessaly, Larissa, Greece; Swedish Medical Center, Englewood, CO; Saint Anthony's Hospital, Lakewood, CO
Session: Oxidation and Macromolecules Saturday, November 22, 2014
- Poster Title: Assessment of catalytic activity and oxidation-reduction potential of custom-synthesized cerium oxide nanoparticles in cell-free systems and tissue.
Author(s):Ana Y. Estevez, Sierra Miller, Quinn R. Self, Joseph S. Erlichman; Saint Lawrence University, Canton, NY
Session: Antioxidants and Novel Therapies Friday, November 21, 2014
- Poster Title: Assessment of Oxidative Stress and Treatment with an Investigational Antioxidant Compound in a Mouse Model of Parkinson's Disease
Author(s): Lisa M. Caputo, MA; Chad E. Beyer, PhD, MBA; Michael P. Neary, BS; Michael J. Zigmond, PhD; Sandra L. Castro; David Bar-Or, MD; Swedish Medical Center, Englewood, CO; Saint Anthony's Hospital, Lakewood, CO; University of Pittsburgh, Pittsburgh, PA
Session: Antioxidants and Novel Therapies Friday, November 21, 2014
About the RedoxSYS Diagnostic System
The RedoxSYS Diagnostic System is a first-in-class clinical diagnostic platform that measures oxidation-reduction potential (ORP) in the body, a homeostatic measurement of oxidative stress that changes in response to injury or illness. The result of nearly two decades of clinical, scientific and technical R&D, the RedoxSYS System is able to provide the only complete assessment of a patient's oxidative status, which has broad diagnostic application across multiple disease areas where oxidative stress is implicated. Luoxis is currently developing RedoxSYS as a simple, rapid blood test for use in the critical care setting, where its ability to provide an objective measurement of patient illness and predict potential complications may enable physicians to improve resource allocation and align higher levels of care with the most critically injured and ill patients, leading to improved outcomes and optimal workflows.
About Luoxis Diagnostics
Luoxis Diagnostics is an in vitro diagnostics company focused on developing and commercializing its proprietary, CE Marked RedoxSYS Diagnostic System. The company is currently developing RedoxSYS to address the $4+ billion critical care market, where it has the potential to provide hospitals with a single, rapid solution with unmatched diagnostic/prognostic value for conditions with significant medical need, and for which few diagnostic biomarkers exist. Luoxis is conducting initial market development for RedoxSYS in select European territories in order to validate and quantify the clinical value of RedoxSYS for monitoring injury severity and patient oxidative stress following traumatic brain injury, multi-trauma injury, and other critical illnesses. Luoxis is also pursuing U.S. regulatory clearance for RedoxSYS, based on completed and ongoing clinical studies in multiple critical care conditions in the United States, including TBI, multi-trauma injury, stroke, sepsis, and other life-threatening conditions. Luoxis has research collaborations in place with leading centers around the world. Luoxis is a majority-owned subsidiary of Ampio Pharmaceuticals, Inc. For more information, visit www.luoxis.com.
About Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc. is a development stage biopharmaceutical company primarily focused on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. We are developing compounds that decrease inflammation by (i) inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; (ii) activating specific phosphatase or depletion of the available phosphate needed for the inflammation process; and (iii) decreasing vascular permeability.
RedoxSYS and Luoxis are trademarks of Luoxis Diagnostics, Inc.
Forward Looking Statement
Ampio's statements in this press release that are not historical fact and that relate to future plans or events are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by use of words such as "believe," "expect," "plan," "anticipate," and similar expressions. These forward-looking statements include risks associated with clinical trials, expected results, regulatory approvals, and changes in business conditions and similar events. The risks and uncertainties involved include those detailed from time to time in Ampio's filings with the Securities and Exchange Commission, including Ampio's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.
For Investors & Media
Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D.: jdrumm@tiberend.com; (212) 375-2664
Amy Wheeler: awheeler@tiberend.com; (646) 362-5750
Logo - http://photos.prnewswire.com/prnh/20130718/MM49747LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/luoxis-to-highlight-redoxsys-at-two-upcoming-scientific-conferences-301699898.html
SOURCE Luoxis Diagnostics, Inc.